US FDA places clinical hold on Tenaya Therapeutics' gene therapy
07/11/2025 21:32
Nov 7 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on Tenaya Therapeutics' TNYA.O trial of its experimental gene therapy for a type of inherited heart disease, the company said on Friday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsTenaya Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tenaya Therapeutics Q2 net loss widens on impairment charge
Brief: Tenaya Therapeutics Q2 Net Income USD -43.393 Million
Brief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401